JW (Cayman) Therapeutics Management
Management criteria checks 3/4
JW (Cayman) Therapeutics' CEO is James Li, appointed in Feb 2016, has a tenure of 8.42 years. total yearly compensation is CN¥20.98M, comprised of 18.4% salary and 81.6% bonuses, including company stock and options. directly owns 5.45% of the company’s shares, worth HK$39.68M. The average tenure of the management team and the board of directors is 2.5 years and 4.1 years respectively.
Key information
James Li
Chief executive officer
CN¥21.0m
Total compensation
CEO salary percentage | 18.4% |
CEO tenure | 8.4yrs |
CEO ownership | 5.5% |
Management average tenure | 2.5yrs |
Board average tenure | 4.1yrs |
Recent management updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | CN¥21m | CN¥4m | -CN¥768m |
Sep 30 2023 | n/a | n/a | -CN¥783m |
Jun 30 2023 | n/a | n/a | -CN¥797m |
Mar 31 2023 | n/a | n/a | -CN¥822m |
Dec 31 2022 | CN¥31m | CN¥3m | -CN¥846m |
Sep 30 2022 | n/a | n/a | -CN¥849m |
Jun 30 2022 | n/a | n/a | -CN¥851m |
Mar 31 2022 | n/a | n/a | -CN¥777m |
Dec 31 2021 | CN¥41m | CN¥2m | -CN¥702m |
Sep 30 2021 | n/a | n/a | -CN¥998m |
Jun 30 2021 | n/a | n/a | -CN¥1b |
Mar 31 2021 | n/a | n/a | -CN¥1b |
Dec 31 2020 | CN¥99m | CN¥3m | -CN¥2b |
Sep 30 2020 | n/a | n/a | -CN¥1b |
Jun 30 2020 | n/a | n/a | -CN¥925m |
Mar 31 2020 | n/a | n/a | -CN¥779m |
Dec 31 2019 | CN¥4m | CN¥3m | -CN¥633m |
Compensation vs Market: James's total compensation ($USD2.89M) is above average for companies of similar size in the Hong Kong market ($USD233.41K).
Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.
CEO
James Li (60 yo)
8.4yrs
Tenure
CN¥20,981,000
Compensation
Dr. Yiping Li, M.D., also known as James, has been a Partner of KPCB China Fund, which is an affiliate of TDF Capital China II, LP, since 2009. He serves as Co-founder and Executive Chairman at JW (Cayman)...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-founder | 8.4yrs | CN¥20.98m | 5.45% CN¥ 39.7m | |
Senior Vice President of Tech Operations | 2yrs | no data | no data | |
Senior VP & Chief Scientific Officer | 2.5yrs | no data | no data | |
Senior Vice President of Corporate Development | 2.5yrs | no data | no data | |
Senior Advisor & Acting Chief Medical Officer | no data | no data | no data | |
Senior VP & Chief Commercial Officer | no data | no data | no data | |
Senior Vice President of Clinical Sciences & Medical Services | no data | no data | no data | |
Senior Vice President Of Clinical Research & PMO | no data | no data | no data | |
Company Secretary | 2.6yrs | no data | no data |
2.5yrs
Average Tenure
46yo
Average Age
Experienced Management: 2126's management team is considered experienced (2.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-founder | 6.7yrs | CN¥20.98m | 5.45% CN¥ 39.7m | |
Independent Non-Executive Director | 1.3yrs | CN¥276.00k | no data | |
Non-Executive Director | 4.1yrs | CN¥331.00k | 1.43% CN¥ 10.4m | |
Independent Non-Executive Director | 3.8yrs | CN¥224.00k | no data | |
Non-Executive Director | less than a year | no data | no data | |
Independent Non-Executive Director | 3.8yrs | CN¥323.00k | no data | |
Independent Non-Executive Director | 4.7yrs | CN¥331.00k | no data | |
Non-Executive Director | 4.2yrs | no data | no data | |
Independent Non-Executive Director | 4.2yrs | CN¥331.00k | no data |
4.1yrs
Average Tenure
57yo
Average Age
Experienced Board: 2126's board of directors are considered experienced (4.1 years average tenure).